{
    "clinical_study": {
        "@rank": "8495", 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate an intravenous (by injection) investigational\n      medication to treat severe ulcerative colitis refractory to steroid therapy.  The research\n      is being conducted at up to 8 clinical research sites in the US and is open to both men and\n      women ages 18 to 70 years old.  Participants in the study will have a number of visits to a\n      research site. All study-related care and medication is provided to qualified participants\n      at no cost: this includes all visits, examinations and laboratory work."
        }, 
        "brief_title": "Research Study in Patients With Severe Ulcerative Colitis", 
        "completion_date": {
            "#text": "November 2005", 
            "@type": "Actual"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase I, dose-escalation, pilot study designed to obtain safety and tolerability data on\n      visilizumab administered to patients with severe ulcerative colitis that has failed to\n      respond to steroid therapy. Patients who are currently receiving IV corticosteroids, but\n      whose disease has not responded after at least 5 days of this therapy, will be eligible for\n      the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. A diagnosis of ulcerative colitis verified by colonoscopy or barium enema performed\n             within 36 months prior to study entry.\n\n          2. Active disease despite ongoing treatment with steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "March 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00032305", 
            "org_study_id": "291-406"
        }, 
        "intervention": {
            "intervention_name": "Visilizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Colitis", 
            "Gastrointestinal Disease", 
            "Digestive System Disease", 
            "Intestinal Disease", 
            "Colonic Disease"
        ], 
        "lastchanged_date": "March 6, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Cedars-Sinai Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "University of California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Atlanta Gastroenterology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "The University of Chicago Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Mount Sinai School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "University of Pittsburgh School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032305"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Facet Biotech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Facet Biotech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Atlanta Gastroenterology Associates": "33.749 -84.388", 
        "Cedars-Sinai Medical Center": "34.052 -118.244", 
        "Mayo Clinic": "44.022 -92.47", 
        "Mount Sinai School of Medicine": "40.714 -74.006", 
        "The University of Chicago Medical Center": "41.878 -87.63", 
        "University of California": "37.775 -122.419", 
        "University of Pittsburgh School of Medicine": "40.441 -79.996"
    }
}